TABLE 3.

Expression of mSpry4 Does Not Significantly Affect β-Cell Carcinogenesis

Age
8 wk
10 wk
12 wk
Dox treatmentWeek 5-8
Week 7-10
Week 10-12
Control*mSpry4Control*mSpry4Control*mSpry4
Tumor incidence/mouseNA5.1 ± 1.1 (N = 12)4.8 ± 1.4 (N = 10)7.1 ± 0.8 (N = 11)8.7 ± 1.6 (N = 7)
P0.87670.3321
Total tumor volume/mouse (μm3)NA13.4 ± 4.8 (N = 12)10.2 ± 4.9 (N = 10)78.3 ± 17.8 (N = 7)45.3 ± 18.0 (N = 11)
P0.64640.2344
Proliferation rate of tumor cells85.0 ± 4.773.6 ± 5.593.2 ± 5.088.2 ± 4.683.7 ± 8.473.1 ± 3.9
n = 70n = 53n = 74n = 72n = 41n = 99
N = 9N = 7N = 9N = 8N = 5N = 12
P0.11680.45930.1958
Apoptotic tumor cells§13.4 ± 0.89.9 ± 0.818.8 ± 1.017.2 ± 1.613.9 ± 0.716.0 ± 0.9
n = 81n = 57n = 89n = 43n = 50n = 75
N = 11N = 7N = 11N = 6N = 8N = 9
P0.00350.38130.0698
  • NOTE: Values represent mean ± SD. P value of mSpry4 vs. control (two-tailed Student's t test). n, number of ×40 microscopic fields. N, number of mice.

  • * Rip1Tag2/Rip1Tag2;Rip1rtTA/Rip1Tag2;(tetO)7mSpry4.

  • Rip1Tag2;Rip1rtTA;(tetO)7mSpry4.

  • Number of BrdUrd-positive cells per ×40 microscopic field.

  • § Number of TUNEL-positive cells per ×40 microscopic field.